MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer

Li,Wenfeng; Liang,Jingjing; Zhang,Zhechao; Lou,Hongyan; Zhao,Liang; Xu,Yunsheng; Ou,Rongying

doi:10.3892/or.2017.5555

MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer

Authors:
- Wenfeng Li
- Jingjing Liang
- Zhechao Zhang
- Hongyan Lou
- Liang Zhao
- Yunsheng Xu
- Rongying Ou
View Affiliations

Affiliations: Laboratory for Advanced Interdisciplinary Research, Center for Personalized Medicine/Institutes of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: April 5, 2017 https://doi.org/10.3892/or.2017.5555
Pages: 2743-2750

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is the second most common gynecological cancer worldwide and remains as one of the leading causes of cancer-related death among women. Despite great progress in the treatment of cervical cancer, the 5-year overall survival rate for patients with this disease remains unsatisfactory. Over the past decade, an increasing number of studies indicate a central role for microRNAs in the initiation and progression of cervical cancer. microRNA‑329-3p (miR-329-3p) has been studied in many types of human cancer; however, the expression level, biological role and the underlying mechanism of miR-329-3p in cervical cancer has not yet been investigated. In the present study, we found that the expression levels of miR-329-3p were reduced in both cervical cancer tissues and cell lines. Low miR-329-3p expression was negatively correlated with histological grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and lymph node metastasis of cervical cancer patients. In addition, upregulation of miR‑329-3p suppressed cell proliferation, migration and invasion of cervical cancer. Furthermore, MAPK1 was identified as a direct target gene of miR-329-3p. MAPK1 was significantly upregulated in cervical cancer tissues and was inversely correlated with miR-329-3p expression in the cervical cancer tissues. Silencing of MAPK1 by RNA interference mimicked the effects of miR-329-3p overexpression on cell proliferation, migration and invasion in cervical cancer. Moreover, rescue experiments showed that restoration of the expression of MAPK1 reversed the effects of miR‑329-3p overexpression in cervical cancer cells. Taken together, these findings suggest that miR-329-3p has a critical tumor-suppressive roles by directly targeting MAPK1 in cervical cancer, and it may be investigated as a novel therapeutic target for the treatment of patients with this disease.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Shi TY, Chen XJ, Zhu ML, Wang MY, He J, Yu KD, Shao ZM, Sun MH, Zhou XY, Cheng X, et al: A pri-miR-218 variant and risk of cervical carcinoma in Chinese women. BMC Cancer. 13:192013. View Article : Google Scholar : PubMed/NCBI
5	Zheng W, Liu Z, Zhang W and Hu X: miR-31 functions as an oncogene in cervical cancer. Arch Gynecol Obstet. 292:1083–1089. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bosch FX and de Sanjosé S: Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003:3–13. 2003. View Article : Google Scholar
7	Yu Y, Zhang Y and Zhang S: MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett. 6:468–474. 2013.PubMed/NCBI
8	Yee GP, de Souza P and Khachigian LM: Current and potential treatments for cervical cancer. Curr Cancer Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wang F, Liu M, Li X and Tang H: MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
10	Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li H and Zhang Z: MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. Tumour Biol. 37:3939–3947. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
12	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
13	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
14	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 96:(Suppl). R40–R44. 2007.PubMed/NCBI
15	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
16	McManus MT: MicroRNAs and cancer. Semin Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
17	Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, Fu L, Zhang L, Wang Z and Li Z: Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 5:1492014. View Article : Google Scholar : PubMed/NCBI
18	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
19	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
20	Zhou J, Li W, Guo J, Li G, Chen F and Zhou J: Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma. Tumour Biol. 37:3561–3569. 2016. View Article : Google Scholar : PubMed/NCBI
21	Jiang W, Liu J, Xu T and Yu X: MiR-329 suppresses osteosarcoma development by downregulating Rab10. FEBS Lett. 590:2973–2981. 2016. View Article : Google Scholar : PubMed/NCBI
22	Xiao B, Tan L, He B, Liu Z and Xu R: MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. J Transl Med. 11:1722013. View Article : Google Scholar : PubMed/NCBI
23	Tsai MM, Wang CS, Tsai CY, Huang HW, Chi HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer. Int J Mol Sci. 17:pii: E945. 2016. View Article : Google Scholar
24	Yang H, Li Q, Zhao W, Yuan D, Zhao H and Zhou Y: miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett. 588:192–197. 2014. View Article : Google Scholar : PubMed/NCBI
25	Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J and Feng F: By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 6:17559–17569. 2015. View Article : Google Scholar : PubMed/NCBI
26	Kang H, Kim C, Lee H, Rho JG, Seo JW, Nam JW, Song WK, Nam SW, Kim W and Lee EK: Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer. Cell Death Differ. 23:484–495. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Lu X, Zhang T, Wen C, Shi M, Tang X, Chen H, Peng C, Li H, Fang Y, et al: mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Oncotarget. 7:21441–21453. 2016.PubMed/NCBI
28	Sun CC, Li SJ, Zhang F, Pan JY, Wang L, Yang CL, Xi YY and Li J: Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget. 7:21510–21526. 2016.PubMed/NCBI
29	Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu D, Feng J, Yang D, Song L and Yan X: MicroRNA 329 suppresses angiogenesis by targeting CD146. Mol Cell Biol. 33:3689–3699. 2013. View Article : Google Scholar : PubMed/NCBI
30	Liang HQ, Wang RJ, Diao CF, Li JW, Su JL and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 6:29413–29427. 2015.PubMed/NCBI
31	Seger R and Krebs EG: The MAPK signaling cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
32	Yiwei T, Hua H, Hui G, Mao M and Xiang L: HOTAIR interacting with MAPK1 regulates ovarian cancer skov3 cell proliferation, migration, and invasion. Med Sci Monit. 21:1856–1863. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhang K, Chen H, Zhang B, Sun J, Lu J, Chen K and Yang H: Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Int J Clin Exp Pathol. 8:608–614. 2015.PubMed/NCBI
34	You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM and You L: Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 6:4357–4368. 2015. View Article : Google Scholar : PubMed/NCBI
35	Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, et al: Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
36	Fei B and Wu H: MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li XW, Tuergan M and Abulizi G: Expression of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis. Asian Pac J Trop Med. 8:937–943. 2015. View Article : Google Scholar : PubMed/NCBI
38	Huang C, Liu LY, Li ZF, Wang P, Ni L, Song LP, Xu DH and Song TS: Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis. Cell Biol Int. 32:1081–1090. 2008. View Article : Google Scholar : PubMed/NCBI
39	Lwin WW, Park K, Wauson M, Gao Q, Finn PW, Perkins D and Khanna A: Systems biology approach to transplant tolerance: Proof of concept experiments using RNA interference (RNAi) to knock down hub genes in Jurkat and HeLa cells in vitro. J Surg Res. 176:e41–e46. 2012. View Article : Google Scholar : PubMed/NCBI